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Abstract
Objective: Cerebral amyloid angiopathy (CAA) is caused by cerebrovascular
deposition of b-amyloid fragments leading to cerebrovascular dysfunction and
other brain injuries. This phase 2, randomized, double–blind trial in patients
with probable CAA assessed the efficacy and safety of ponezumab, a novel
monoclonal antibody against Ab1–40. Methods: Thirty-six participants aged 55–
80 years with probable CAA received intravenous placebo (n = 12) or ponezu-
mab (n = 24). The change from baseline to Days 2 and 90 in cerebrovascular
reactivity (CVR) was measured in the visual cortex as the natural log of the ris-
ing slope of the BOLD fMRI response to a visual stimulus. Safety and tolerabil-
ity were also assessed. Results: The mean change from baseline to Day 90 was
0.817 (ponezumab) and 0.958 (placebo): a mean ratio of 0.852 (90% CI 0.735–
0.989) representing a trend towards reduced CVR in the ponezumab group.
This trend was not present at Day 2. There was one asymptomatic occurrence
of amyloid–related imaging abnormality–edema in the ponezumab group. The
total number of new cerebral microbleeds from baseline to day 90 did not differ
between groups. The ponezumab group had a participant with nonfatal new
cerebral hemorrhage with aphasia and a participant with subdural hemorrhage
that site investigators deemed to be nondrug related. In the placebo group one
participant had a fatal intracerebral hemorrhage and one participant had
migraine with aura. Interpretation: Ponezumab was safe and well-tolerated.
The ponezumab group showed a trend towards treatment effect at Day 90 that
was opposite to the hypothesized direction. The prespecified efficacy criteria
were thus not met.
Introduction
Cerebral Amyloid Angiopathy (CAA) is a progressive neu-
rovascular disease characterized by deposition of the b-
amyloid peptide, especially Ab1–40, in the walls of cortical
and leptomeningeal vessels.1 Accumulation of b-amyloid
leads to cerebrovascular dysregulation, lobar cerebral hem-
orrhages, microbleeds, cortical superficial siderosis, and
nonhemorrhagic forms of brain injury such as white matter
lesions and microinfarcts. Collectively, these brain injuries
result in impaired cognitive and motor function.1 These
clinical symptoms can resemble or coexist with those of
other neurodegenerative conditions such as Alzheimer’s
Disease (AD), leading to underestimation of its preva-
lence.2 Comorbidity of CAA and AD is common, and CAA
contributes to the clinical manifestations seen in AD–re-
lated dementia3 and to the Amyloid–Related Imaging
Abnormalities (ARIA) identified in trials of antiamyloid
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immunotherapy.4 Estimates suggest that greater than 30%
of the individuals over age 65 may have at least some
underlying CAA.1,5 Vascular dysfunction likely mediates
ischemic consequences of CAA such as leukoaraiosis,
microinfarction, and cortical atrophy6–9 and thus con-
tribute to CAA–related cognition and gait, impairments.
T2*-weighted Magnetic Resonance Imaging (MRI) can
reveal the presence of characteristic hemorrhages. Another
MRI modality, visual stimulus–driven functional MRI (fMRI),
has been used to evaluate the markedly impaired vascular
regulation that accompanies CAA.10–12 The fMRI biomarkers
constitute radiologic surrogates for vascular dysfunction and
open the possibility of detecting neurophysiologic changes in
response to treatment in a relatively short period of time.
Passive immunotherapy has been proposed as a means
of targeting circulating amyloid and plaques for treatment
of degenerative diseases associated with brain amyloid
deposition such as AD or CAA.13–15 It is conceivable that,
by decreasing vascular amyloid, vascular dysfunction in
CAA could be improved, potentially leading to a
decreased ischemic injury and resultant cognitive decline.
Ponezumab is a humanized immunoglobulin G2
(IgG2) monoclonal antibody targeted against an epitope
encompassing the C-terminal amino acids of the Ab1–40
peptide derived from the human amyloid precursor pro-
tein (APP). Mutations (A330S and P331S) in the IgG2Da
Fc region are intended to minimize the ability of ponezu-
mab to activate complement or support antibody-depen-
dent cell-mediated cytotoxicity. As Ab1–40 is the
predominant species present in blood vessel walls, pone-
zumab was developed to prevent or reverse b-amyloid
aggregation and deposition and thus prevent or reduce
CAA progression with minimal ARIA risk.15
The current study sought to assess the safety, tolerabil-
ity, and efficacy of intravenous ponezumab versus placebo
for improving vascular reactivity in adult participants
with CAA (NCT01821118).
Methods
Study design
This was a phase 2, randomized, double–blind, parallel
group, placebo–controlled trial examining the effects of
intravenous (IV) ponezumab in adults with probable
CAA.16,17 The study was intitiated at eleven sites and con-
ducted at ten sites in five countries: USA (5), Canada (2),
UK, Netherlands, and France (1 each). The primary effi-
cacy endpoint was change from baseline to Day 2 or Day
90 in cerebrovascular reactivity measured by blood oxy-
genation level dependent (BOLD) fMRI in response to
visual stimulation. Safety, tolerability, and pharmacokinet-
ics (PK) of ponezumab were also assessed.
Inclusion/exclusion criteria
The study included men and women of nonchildbearing
potential ages 55–80 with probable CAA per the modi-
fied Boston criteria16,17 and an acceptable structural MRI
scan in the previous 12 months. Study participants were
also required to have corrected vision at 20/50 or better
on a Snellen chart. Potential participants were excluded
if their CAA disease resulted in cognitive or functional
deficits as documented by the Principal Investigator (PI)
in consultation with the sponsor. Other exclusions
included: clinical diagnosis of probable AD dementia or
significant cognitive impairment (defined as a score of
<26 on the Mini Mental State Examination [MMSE]);
history of cancer within the last 5 years (except for
excised cutaneous basal or squamous cell cancer
resolved, excised colonic polyp, or nonprogressive pros-
tate cancer per investigator’s judgment); baseline BOLD
fMRI of insufficient quality; uncontrolled hypertension;
use of concomitant anticoagulation medications, antiin-
flammatory treatments given for CAA, or cognition–af-
fecting drugs (anticholinergics and acetylcholinesterase
inhibitors/memantine).
Study drug administration
Ponezumab or placebo was administered by IV infusion
in a total volume of 100 mL over 10–15 min. Ponezumab
was administered at a dose of 10 mg/kg at Day 1 followed
by 7.5 mg/kg at Days 30 and 60.
Primary and secondary efficacy endpoints
The primary efficacy endpoint was change from baseline
to Day 2 or Day 90 in cerebrovascular reactivity as mea-
sured by the natural logarithm of the slope of the visual
stimulus–driven fMRI BOLD response. The slope was
chosen as the primary endpoint based on a linear dis-
criminant analysis of previous study data10 where the
modelled amplitude of the hemodynamic response func-
tion divided by the time to reach the peak amplitude (on
a logarithmic scale) was found to provide better differen-
tiation from controls by incorporating both the reduced
amplitude and delayed time to peak associated with CAA.
The secondary efficacy endpoints were change from base-
line to Day 2 or to Day 90 in cerebrovascular reactivity
measured by the individual parameters for time to peak,
amplitude, and time to baseline from the time-course of
the visual stimulus–driven fMRI hemodynamic response.
The secondary pharmacodynamics (PD) endpoint was
change from baseline in total plasma Ab1–40 concentra-
tions at Days 1, 2, 30, 90, and 240. Ab1–40 concentrations
were measured using the V-PlexTM Ab Peptide Panel 1
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(6E10) Kit (Meso Scale Diagnostics, Rockville, MD, USA)
followed by solid phase extraction. Pharmacokinetic (PK)
samples were analyzed for ponezumab concentrations
using a validated, sensitive, and specific enzyme–linked
immunosorbent assay (ICON Laboratory Services Inc.,
Whitesboro, New York, NY, USA).
Magnetic resonance imaging
BOLD fMRI scans (GE-EPI acquired at TR = 1.5 sec,
TE = 27–30 msec, FA = 75°, res = 3.4 9 3.4 mm2, thick-
ness = 2.9–3.0 mm) were performed during visual stimu-
lation at baseline, Day 2, and Day 90. The details of the
acquisition parameters were selected to mimic those pre-
viously published10 with modifications in echo time and
flip angle values to optimize functional contrast at 3 T
instead of 1.5 T. The temporal resolution of the image
sampling was not compromised by the modifications and
the number of presentations (four per run) and on/off
frequency of the stimulus presentation (20 sec on/28 sec
off) did not change from the prior reports. The visual
stimulus was a standard 8 Hz flashing black-and-white
radial checkerboard image alternating with a gray screen.
Participant attention during the scan was assessed using a
color–changing dot in the screen center that changed
color at random intervals between 0.25 and 3.75 sec; par-
ticipants were instructed to press a button when the dot
color changed.10,18 The BOLD fMRI time–course was
used to assess vascular reactivity. All efficacy scans were
analyzed centrally, according to standardized procedures
and quality assurance (QA)/quality control (QC) guide-
lines (IXICO, Ltd., London, UK).
Structural MRI scans were performed at screening and
Days 15, 45, and 90. T2-weighted, T2*-weighted, and fluid-
supressed T2-weighted images were acquired for central
detection of cerebral microbleeds (CMBs), infarcts, white
matter hyperintensity, or ARIA–hemorrhage type (ARIA-
H) or ARIA–edema type (ARIA-E) per Alzheimer Associa-
tion Research Roundtable Working Group standards.4 For
T2*-weighted images, TE was nominally 20–25 msec, with
in-plane resolution approximately 1 mm2 and slice thick-
ness 5 mm. A standard high-resolution T1-weighted image,
based on ADNI2 parameters,19 was also acquired. All scans
were performed on 3T scanners (Siemens, Philips, GE) and
all scans analyzed centrally according to rigorous standard-
ization and quality guidelines (IXICO, Ltd., London, UK).
Image analysis
Functional image series were first registered to each par-
ticipant’s high-resolution T1-weighted structural image,
then warped into Montreal Neurological Institute (MNI)
space, and resampled at 2 mm using IRTK software
(BioMediaIA, London, UK). Preprocessing continued in
the FSL software toolkit (Oxford Centre for Functional
MRI of the Brain, Oxford, UK) with motion correction,
nonlinear noise reduction (SUSAN), spatial smoothing
with a 5-mm Gaussian kernel, temporal filtering, and
prewhitening. The FLOBS tool in FSL was then used to
generate a hemodynamic response function basis set with
three components that had sufficient flexibility to account
for a large array of temporal delays expected in the data,
and a general linear model used to fit the time–series data
with the FSL tool FEAT. Region of Interest (ROI) analyses
were performed using the FSL tool Featquery within two
functionally defined regions in the occipital lobe. These
ROIs (Fig. 1) were derived from an independent dataset
from CAA participants acquired at 1.5 T,10 then mapped
into MNI space for use across participants. The primary
and secondary ROIs for the analysis were defined by the
voxels activated in at least 50% or at least 25%, of the
runs across all CAA participants, respectively. The primary
ROI for the analysis, ROI1, was used to extract the mean
of the modeled time–courses within the ROI. A larger sec-
ondary ROI, ROI2, was used to extract a z-score–weighted
mean of the modeled voxel-wise time-courses within the
ROI. To generate summary metrics of the hemodynamic
response, trial–averaged mean and z-score–weighted mean
modeled time courses from ROI1 and ROI2, respectively,
were fit with a trapezoid. This strategy was chosen so that
hemodynamic response metrics of amplitude, time to
peak, and time to baseline could easily be compared with
previous work using the same approach.10 To exclude
contamination from severely impaired tissue, each ROI
was also split into left and right cerebral hemispheres,
generating separate unilateral modeled time–courses,
which were each fit with a trapezoid. The decision to use
the left hemisphere, right hemisphere, or full ROI for lon-
gitudinal analysis was determined for each participant
based only on activation and trapezoid model fit quality
standards applied to baseline functional runs.
Safety evaluations
The safety endpoints included changes from baseline on
physical and neurological assessments, Montreal Cognitive
Assessment (MoCA), Columbia Suicide Severity Rating
Scale (C-SSRS), laboratory assessments, 12-lead electro-
cardiogram (ECG), vital signs, immunogenicity, and
adverse event (AE) monitoring. AEs were judged for likely
relationship to treatment by the site investigator and
reviewed by the central medical monitor; all determina-
tions were performed without knowledge of treatment
assignment. Structural MRI scans were read centrally for
abnormalities such as ARIA-H, ARIA-E, and changes in
CMB counts. CMB assessments were performed visually
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on standard, multi-slice axial T2*-weighted images. To
mitigate longitudinal variability in CMB counts and so
that emergent CMBs were more readily identifiable, read-
ers blinded to treatment assignment labeled CMBs in
their read system and images were viewed side-by-side
with those from previous visits. All safety scans were
interpreted centrally (IXICO, Ltd., London, UK), accord-
ing to standardized procedures and QA/QC guidelines.
Statistical methods
Sample size calculations were based on an estimate of the
variability obtained from previous study data.10 In
addition to the variability estimate, these data also pro-
vided informative priors for placebo effects at 1 day and
3 months. The Bayesian approach, a statistical technique
to incorporate prior information into data analysis, was
utilized in the study, and the inclusion of the derived pri-
ors was expected to provide an equivalent of nine addi-
tional evaluable placebo participants for the study.
Based on the primary endpoint of cerebrovascular reac-
tivity measured by the natural logarithm of the slope in
visual stimulus–driven fMRI and utilizing the Bayesian
informative prior on placebo, it was estimated that a sam-
ple size of 30 evaluable study participants – 20 ponezu-
mab and ten placebo (approximately 1:1 ratio expected in
Figure 1. Locations of Regions of Interest (ROI). ROI1 is shown on the left, and ROI2 is shown on the right.
798 ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Ponezumab Immunotherapy in Probable CAA C. Leurent et al.
analysis combined with the informative placebo prior) –
was required to provide enough precision for a 2-part
predefined criteria for efficacy: C1: point estimate of
ponezumab versus placebo effect >20% increase (im-
provement) in slope; C2: standard error of ponezumab
versus placebo effect <60% of the point estimate. Given
an expected dropout rate/technical failure of 16.7%, a
total of 36 participants were planned for randomization.
For the primary endpoint, the Full Analysis Set (FAS;
all participants who received at least one postdose efficacy
measurement) was analyzed using an analysis of covari-
ance (ANCOVA) model with treatment as a fixed effect
and baseline as a covariate, conducted within a Bayesian
framework utilizing the prederived informative prior for
the placebo effect. An observed case approach (i.e., miss-
ing data excluded) was used, and an outlier–robust model
was utilized in Bayesian modelling to down-weight the
influence of potential outliers. Sensitivity analyses using
low informative prior only (i.e., essentially without prior
information), Last Observation Carried Forward (LOCF),
or all equally weighted data (i.e. outliers included), were
also performed. The analysis was performed separately for
Day 2 and Day 90. Analysis was performed on a natural
logarithm (loge) scale.
For the analysis of secondary efficacy endpoints, analysis
of change from baseline in time to peak, amplitude, and
time to return to baseline was performed on a loge scale.
Change from baseline in loge (time to peak) for Days 2
and 90 was analyzed using the same Bayesian method
using an observed case approach (i.e., missing data
excluded). Analyses were based on the FAS and used an
outlier–robust model. The other secondary endpoints from
the visual stimulus–driven fMRI (change from baseline in
loge[amplitude] and loge[time to return to baseline]) were
analyzed using ANCOVA with loge(baseline value) as a
covariate. These analyses were also based on the FAS and
analyses were performed separately for Days 2 and 90.
Ponezumab plasma concentrations were summarized
and plotted for participants in the PK analysis set: all par-
ticipants in the FAS for whom there was at least one pone-
zumab plasma concentration. The PD analysis set
consisted of all participants in the FAS with at least one
plasma Ab concentration. Plasma Ab was plotted against
plasma ponezumab concentrations and the relationship
between ponezumab plasma concentration and percent
change from baseline to Days 2 and 90 for slope and time
to peak were assessed by linear regression. For immuno-
genicity analysis, the proportion of participants with a
measurable antibody response to ponezumab was summa-
rized for each visit. Safety data were evaluated using
descriptive statistics. The statistical analysis software pack-
age (SAS version 9.2, SAS Institute, Cary, NC, USA; Open-
BUGS 3.2.3, rev 1012, Members of the OpenBUGS Project
Management Group, Medical Research Council Biostatis-
tics Unit, Cambridge UK, and Imperial College School of
medicine, London UK) was used for all analyses.
Results
Between 25 June 2013 and 20 January 2015, 67 partici-
pants were screened for study entry and 36 were random-
ized to treatment: 24 to ponezumab and 12 to placebo
(Fig. 2). Thirty-five completed the study. All 36 random-
ized participants were included in the FAS and the safety
analyses.
Demographic and baseline characteristics are listed in
Table 1. A majority of participants were male (23/36),
≥65 years (24/36 participants), and white (35/36 partici-
pants). Compared with the placebo group, nonsignifi-
cantly greater numbers of participants in the ponezumab
group had moderate baseline white matter hyperintensi-
ties (13/24 ponezumab vs. 5/12 placebo) and baseline
CMB counts > 300 (6/24 ponezumab vs. 1/12 placebo).
There was also an imbalance in apolipoprotein E geno-
type, with 50% of the ponezumab participants with the
E3/E4 or E4/E4 genotype versus 25% in the placebo
group.
For the primary efficacy endpoint, the geometric mean
change from baseline in the BOLD fMRI slope on Day 2
was 0.954 in the ponezumab group compared with 0.969
in the placebo group giving a geometric mean ratio
(ponezumab vs. placebo) of 0.984 with a 90% credible
interval of 0.820–1.184. For Day 90, the geometric mean
change from baseline in the BOLD fMRI slope was 0.817
in the ponezumab group compared with 0.958 in the pla-
cebo group, giving a geometric mean ratio for ponezu-
mab versus placebo of 0.852 with a 90% credible interval
of 0.735–0.989 (Fig. 3 and Table 2) – that is, the slope of
the fMRI response was shallower in the ponezumab group
than the placebo group, contrary to the prespecified
hypothesis. Thus, the predefined efficacy criteria for
increased vascular reactivity were not met either at Day 2
or Day 90. Similarly, for the secondary fMRI endpoints
(change in time to peak, amplitude, and time to return to
baseline), ponezumab treatment showed negligible mean
changes at Day 2 while at Day 90, the mean observed dif-
ferences were opposite to the hypothesized direction;
none of these values were statistically significant at the
5% level. Sensitivity analyses on primary or secondary
ROIs, with or without informative Bayesian priors, were
also conducted and provided consistent results. Post hoc
analysis in which participants with CMB counts >300
were excluded did not change the findings for the pri-
mary endpoint. Additionally, post hoc analyses with
apolipoprotein E status, CMB count (log-transformed),
or white matter hyperintense lesion percentage as
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covariates did not change the primary results. In analyses
that used a Bayesian approach, the study placebo group
yielded responses consistent with the prespecified placebo
priors derived from previous fMRI study data.10
Ponezumab plasma concentrations peaked 1 h postdose
with mean concentration 239.1 lg/mL on Day 1. Mean
trough concentrations on Days 30, 60, and 90 were
46.1 lg/mL, 60.37 lg/mL, and 83.02 lg/mL, respectively.
These findings were consistent with those from previous
ponezumab AD trials.20 Robust and cumulative increases
from baseline in plasma Ab1–40 were observed after pone-
zumab dosing in all participants, whereas plasma Ab1–40
levels in the placebo group were low and stable as
expected (Fig. 4; mean (range): 4747.6 (3054–7154) pg/
mL and 87710.8 (59418–131756) pg/mL for Day1 8 h
post dose and Day 90 respectively in the ponezumab
group, and 8.4 (55–42) pg/mL and 0.7 (61–88) pg/
mL for Day1 8 h post dose and Day 90 respectively in
the placebo group). The mean plasma Ab1–40 concentra-
tion, presented as placebo–adjusted change from baseline
at Day 1 time zero, was 68.0 ng/mL and 87.7 ng/mL at
Day 30 and Day 90, respectively. A hysteresis relationship
was observed between ponezumab plasma concentrations
and plasma Ab1-40 levels, likely due to a longer terminal
half-life of plasma Ab1–40. Qualitative assessment of expo-
sure–response analysis revealed no relationship between
trough ponezumab plasma concentration and BOLD
fMRI response slope or time to peak change.
Figure 2. CONSORT flow diagram.
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The safety profile of ponezumab was consistent with
previous studies in AD and consistent with the profile of
the general CAA population.20 In the ponezumab group
one participant had nonfatal cerebral hemorrhage associ-
ated with aphasia and one participant had a subdural
hematoma, both of which were determined by the site
investigators not to be treatment related. In the placebo
group there was one fatal occurrence of intracerebral
hemorrhage and one occurance of migraine with aura. At
screening, the median (range) lobar CMB count was 40.5
(0.0–881.0) and 19.5 (2.0–1113.0) in the ponezumab and
placebo groups, respectively. No notable changes in CMB
incidence from screening to Day 90 were observed
(Table 3). There was one instance of asymptomatic
ARIA-E at Day 90 in the ponezumab group (Fig. 5) in
which cognition was unchanged, as measured by MoCA.
No participants developed antidrug antibodies. There
were no notable changes in laboratory analysis, vital signs,
ECGs, physical examinations, structural brain MRI find-
ings, cognition, or suicidality.
Discussion
In this study in adults with probable CAA per the modi-
fied Boston criteria, treatment with the humanized anti-
Ab1–40 antibody, ponezumab, was safe and well-tolerated,
with minimal safety concerns. There were no deaths or
treatment–related serious adverse events, as judged by the
site investigator and central medical monitor, in the pone-
zumab treatment group. Advanced CAA is associated with
a spontaneous inflammatory syndrome resembling ARIA-
E – apparently driven by anti-Ab autoantibodies in cere-
brospinal fluid21,22 – that has been postulated to occur by
similar mechanisms as treatment–related ARIA-E.4 Exoge-
nous anti-Ab antibody treatment of CAA patients might
therefore have been expected to trigger a significant
increase in ARIA-E. There was little evidence of ARIA-E in
these participants with probable CAA, however, with a
single occurrence of asymptomatic ARIA-E at Day 90 in
the ponezumab group in an apolipoprotein Ee4 noncarrier
deemed by the site investigator not to be treatment-
related, and no apparent increase in ARIA-H. A possible
contributing factors to the low incidence of treatment–re-
lated ARIA-E in this trial may be the particular character-
istics of the monoclonal antibody ponezumab.
Although there was no apparent evidence for treatment–
associated increase in ARIA-H, it should be noted that
consistent enumeration of microbleeds can be challenging,
particularly when the burden is high, the microbleeds are
small, or are in close proximity to each other or other sus-
ceptibility–related signal voids. The partial volume of small
microbleeds within the relatively thick T2*-weighted slices
also means that small differences in participant positioning
and slice angulation can reduce the consistency of the
microbleed count. While every effort was made to ensure
consistent head placement and image slice planning, small
differences are largely unavoidable. Automating microbleed
detection may improve consistency in future studies.
Table 1. Demographics and baseline characteristics.
Ponezumab
(n = 24)
Placebo
(n = 12)
Gender, Male (%) 16 (66.7) 7 (58.3)
Age, Mean (SD) 68.8 (6.8) 65.0 (5.7)
Weight, Mean (SD) kg 75.3 (14.5) 73.5 (12.1)
BMI, Mean (SD) kg/m2 25.9 (3.0) 25.2 (3.7)
Height, Mean (SD), cm 169.6 (10.5) 170.6 (11.9)
Lobar CMB (%)
0–10 8 (33.3) 5 (41.7)
11–40 4 (16.7) 3 (25.0)
41–100 2 (8.3) 1 (8.3)
101–300 4 (16.7) 2 (16.7)
>300 6 (25.0) 1 (8.3)
Overall (>0) 23 (95.8) 12 (100.0)
Intracranial hemorrhage 13 (54.2) 6 (50.0)
Superficial siderosis 14 (58.3) 7 (58.3)
White matter hyperintensities
Absent 1 (4.2) 2 (16.7)
Mild 8 (33.3) 4 (33.3)
Moderate 13 (54.2) 5 (41.7)
Severe 2 (8.3) 1 (8.3)
Apolipoprotein E genotype:
E2/E3 2 (8.3) 0
E2/E4 4 (16.7) 2 (16.7)
E3/E3 6 (25.0) 7 (58.3)
E3/E4 5 (20.8) 1 (8.3)
E4/E4 7 (29.2) 2 (16.7)
MMSE, mean (SD) 28.8 (1.24) 28.8 (1.06)
MoCA, mean (SD) 25.5 (3.41) 25.9 (3.34)
Stable use of antiepileptic drug 3 (12.5) 0
Stable use of antiinflammatory drug:
For treatment of CAA1 0 0
For treatment of other
condition2
3 (12.5) 1 (8.3)
Baseline BOLD fMRI parameters3, mean (SD)
Slope (percent/second) 0.12 (0.08) 0.15 (0.06)
Time to peak (seconds) 11.92 (1.85) 11.39 (2.12)
Amplitude (percent) 1.36 (0.71) 1.69 (0.59)
Time to return to baseline
(seconds)
12.17 (1.63) 11.91 (1.95)
Abbreviations: BOLD, blood oxygenation level dependent; CAA, cere-
bral amyloid angiopathy; CMB, cerebral microbleeds; fMRI, functional
magnetic resonance imaging; MMSE, Mini Mental State Examination;
MoCA, Montreal Cognitive Assessment; n, number of subjects; ROI,
region of interest; SD, standard deviation.
1Include aspirin and oral/intravenous steroids.
2Include any nonsteroidal antiinflammatory drugs and topical/oral/in-
travenous steroids.
3BOLD fMRI parameters were from ROI1.
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Plasma ponezumab concentrations were consistent with
those observed in previous trials of ponezumab in AD at
similar dose regimen.20 Compared with placebo, plasma
Ab1-40 concentrations increased cumulatively after multiple
ponezumab administrations, with peak concentrations
observed on Day 90 (30 days post last dose). These findings
were consistent with previous observations showing tran-
sient mobilization and stabilization of Ab1–40 deposits by
ponezumab peripherally.20,23,24
For the primary endpoint of change from baseline in
natural logarithm of the slope of visual stimulus-driven
fMRI responses, ponezumab showed negligible mean
treatment effect at Day 2 and marginally negative mean
treatment effect at Day 90. At both timepoints, the pla-
cebo group remained stable, but the direction of any
mean treatment effect was opposite to the hypothesized
direction. As such, the treatment did not produce the
expected improvement in the radiologic surrogate of
Figure 3. Primary outcome for loge(slope) change from baseline, mean  SE.
Table 2. Change from baseline in the primary efficacy endpoint of BOLD fMRI slope at Days 2 and 90, ROI1.
Treatment
group n
Geo-
metric
mean SE1 90% CI2
Geo-
metricmean
ratio SE1 90% CI2
Mean/
SE1
Probability
(Treatment
Effect>x),
where x=
C13
achieved
C24
achieved0% 20%
Day 2
Ponezumab 20 0.954 0.085 (0.831, 1.096) 0.984 0.112 (0.820, 1.184) 0.146 0.4367 0.0390 No No
Placebo 11 0.969 0.073 (0.861, 1.092)
Day 90
Ponezumab 20 0.817 0.064 (0.736, 0.908) 0.852 0.091 (0.735, 0.989) –1.761 0.0390 0.0002 No No
Placebo 10 0.958 0.063 (0.864, 1.064)
The units for slope are percent/second.
Abbreviations: BOLD, blood oxygenation level dependent; CI, credible interval; fMRI, functional magnetic resonance imaging; n, number of sub-
jects; ROI, region of interest; SE, standard error.
1Log scale value presented.
2A credible interval was defined as a posterior probability interval.
3Point estimate of ponezumab versus placebo effect >20% increase (improvement) in slope.
4Standard error of ponezumab versus placebo effect <60% of the point estimate.
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vascular dysfunction, and the prespecified criteria for effi-
cacy were not met at either Day 2 or 90. The individual
fMRI secondary endpoints were in line with primary end-
point observations.
The failure to meet the primary endpoint may indicate
that vascular amyloid was not cleared, or perhaps not suf-
ficiently cleared, to improve vascular reactivity. The unex-
pected trend towards a decrease in vascular reactivity
estimated via fMRI could be due to mobilization of amy-
loid plaque,25 mobilization of vascular amyloid with
resultant vascular damage, the possibility of a random
chance finding associated with a small sample size, or a
currently unidentified effect of antiamyloid immunother-
apy.
The large gamut of clinical, radiologic, and laboratory
data obtained longitudinally did not show any concerning
changes in the ponezumab group, so there is no indica-
tion that the reduced slope observed on fMRI represents
a clinically meaningful worsening. As the BOLD fMRI sig-
nal is influenced by a combination of neurometabolic,
vascular, and hemodynamic responses to the visual stimu-
lus, a definitive biological interpretation of the observed
fMRI time–course is not currently possible. Further, the
timing and direction of the vascular reactivity response to
amyloid–removing therapy is unknown, as this is the first
study of this kind. It is possible that the removal of amy-
loid from the vessel wall triggers a transient increase in
cerebrovascular dysfunction. Future studies employing
this fMRI technique could consider additional time points
to more fully characterize the response.
The consistency of baseline and placebo data in this
study, together with the fMRI results from previously
Figure 4. Mean plasma Ab1–40 concentration versus time.
Table 3. Summary of cerebral microhemorrhage frequency.
Placebo Ponezumab
(N = 12) (N = 24)
Day 0 Day 15 Day 45 Day 90 Day 0 Day 15 Day 45 Day 90
Median 19.5 19.5 19.5 20.5 40.5 41.5 41.5 44.0
Range 2–1113 2–1114 2–1114 2–1114 0–881 0–881 0–881 0–883
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Figure 5. FLAIR and T2*-weighted images of ARIA-E event. (A) FLAIR (top row) and T2*-weighted images (bottom row) taken at baseline (left),
Day 45 (middle) and Day 90 (right). The arrow in the Day 90 FLAIR image indicates the presence of new ARIA-E, and the associated T2*-
weighted image at Day 90 shows a new colocalized subarachnoid hemorrhage. Baseline findings in this subject included multiple areas of
superficial siderosis of both cerebral hemispheres. (B) Baseline findings also included four old parenchymal macro-hemorrhages, as show in three
different levels in the baseline T2-weighted images.
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published studies,12 suggest that it is feasible to use the
technique in a consistent manner across multiple study
timepoints and sites, so it may become a viable bio-
marker for future studies.10,12 Our results were unique
in suggesting that a pharmacologic intervention might
cause a consistent change in these fMRI markers. The
exact physiologic determinants of these markers and
the clinical implications of altering them remain to be
determined.
Limitations of this study include the relatively small
sample size, relatively short duration of treatment, and
limited number of timepoints. Another potential limita-
tion is misdiagnosis of CAA, though we note that the
modified Boston criteria appear to have high specificity
(87.5% to 100%) among symptomatic patients. The novel
finding of a tendency towards apparent reduced vascular
reactivity with little evidence of ARIA or other overt
inflammatory effects raises the possibility of a previously
unidentified effect of antiamyloid immunotherapy that
may be worthy of further investigation.
Future CAA studies should employ advanced brain
imaging to disentangle the potential cause–effect relation-
ships between amyloid load and vascular function and
may help us understand how pharmacologic interventions
can modify these important parameters to obtain a bene-
ficial clinical effect.
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